Maze Therapeutics, a clinical-stage biopharmaceutical company, has successfully completed a $115 million Series D financing round aimed at advancing its clinical programs. This funding will support the development of innovative treatments for patients suffering from renal, cardiovascular, and metabolic diseases.
Key Takeaways
Maze Therapeutics raised $115 million in an oversubscribed Series D financing.
The funding will advance lead programs MZE829 and MZE782.
MZE829 targets APOL1 kidney disease, with a Phase 2 trial expected in early 2025.
MZE782 is being evaluated for chronic kidney disease and phenylketonuria.
The financing was co-led by Frazier Life Sciences and Deep Track Capital.
Overview Of The Financing
Maze Therapeutics announced the completion of its Series D financing, which included the conversion of previously issued convertible notes from existing investors. The round was co-led by Frazier Life Sciences and Deep Track Capital, with participation from Janus Henderson Investors and Logos Capital, among others.
This financing round reflects the confidence investors have in Maze's innovative approach to developing precision medicines. The company has a strong backing from notable investors, including Third Rock Ventures, ARCH Venture Partners, and Andreessen Horowitz.
Advancements In Clinical Programs
The funds raised will primarily support the advancement of Maze’s lead clinical programs:
MZE829: An oral APOL1 inhibitor aimed at treating APOL1 kidney disease (AKD), particularly in patients with focal segmental glomerulosclerosis (FSGS). A Phase 2 trial is anticipated to commence in the first quarter of 2025.
MZE782: An oral SCL6A19 inhibitor currently in a Phase 1 trial with healthy volunteers. This program is being evaluated for its potential in treating chronic kidney disease (CKD) and phenylketonuria (PKU), with data expected in the latter half of 2025.
Company Vision And Future Plans
Jason Coloma, Ph.D., CEO of Maze Therapeutics, expressed gratitude for the continued support from long-term investors and emphasized the importance of this financing in optimizing the upcoming Phase 2 trial of MZE829. He stated, "This financing marks an important step in our growth as a company, and for the patients we aim to serve."
The company aims to leverage its Compass Platform, which utilizes insights from human genetics to develop targeted therapies. This platform is crucial for linking genetic variants to the biological pathways that drive diseases in specific patient populations.
Investor Insights
Investors have highlighted the potential impact of Maze's innovative approach on the treatment landscape for kidney diseases. James Brush, M.D., from Frazier Life Sciences, noted that Maze is well-positioned to address key drivers of disease for patients living with CKD, AKD, FSGS, and PKU.
Rebecca Luse, Principal of Deep Track Capital, emphasized the significance of Maze’s programs in providing transformative healthcare solutions, stating, "Maze has two significant opportunities with MZE829 and MZE782 to disrupt the treatment landscape for people with kidney disease."
Conclusion
The successful completion of the $115 million financing round marks a pivotal moment for Maze Therapeutics as it continues to advance its clinical programs. With a strong focus on precision medicine and a commitment to addressing unmet medical needs, Maze is poised to make significant contributions to the treatment of renal and metabolic diseases in the coming years.
Sources
Maze Therapeutics Announces Oversubscribed $115 Million Financing to Support Advancement of Clinical-Stage Programs and Future Pipeline | Business Wire, Business Wire.
Комментарии